https://www.avient.com/sites/default/files/2020-05/1.-polyone-ir-presenstation-fermium-research-chemicals-conference.pdf
Microsoft PowerPoint - PolyOne Investor Presentation 5.4.20_v8 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • P E O P LE P RO D U CT S P LA N E T P E RF O R MAN C E •• •• •• JVs Performance Products & Solutions Distribution Specialty To be the world’s premier provider of specialized polymer materials, services and solutions To be the world’s premier provider of specialized polymer materials, services and sustainable solutions • • • • • • • • • • • • • • 2016 2017 2018 2019 Lightweighting Reduced Material Requirements Improved Recyclability Renewable Energy Applications Eco-conscious Bio-derived Content Reduced Energy Use VOC Reduction $275M $325M $355M $410M 14% Total Annual Growth 9% Organic Annual Growth PolyOne Corporation 33 Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018*** Q1 2019*** 2019 Q1 2020 Net income from continuing operations attributable to PolyOne common shareholders Joint venture equity earnings, after tax Special items, before tax(1) Special items, tax adjustments(1) Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1 (19.0) (14.7) (3.7) — — — — — — — — — — — (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6 (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0) $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation. ** Pro forma for sale of Designed Structures and Solutions segment (DSS). *** Pro forma for sale of Performance Products and Solutions segment (PP&S).
Reconciliation to Adjusted EPS Excluding Special Items and Impacts of February 2020 Equity Offering Three MonthsEnded March 31, 2020 Net income from continuing operations – GAAP $ 33.1 Special items, after tax(1) 8.6 After tax interest income earned on equity proceeds, included in Interest expense, net (0.7) Adjusted net income excluding special items and impact of interest income on equity proceeds $ 41.0 Diluted weighted-average shares used to compute earnings per common share 86.7 Weighted-average impact of 15.3 million shares issued in February 2020 equity offering (9.3) Diluted weighted-average shares excluding impact of shares issued in February 2020 equity offering 77.4 Adjusted EPS - excluding special items and the net impact of equity offering $ 0.53 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to PolyOne shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to PolyOne shareholders, excluding special items, to assess performance and facilitate comparability of results.
Senior management believes these measures are useful to investors because they allow for comparison to PolyOne's performance in prior periods without the effect of items that, by their nature, tend to obscure PolyOne's operating results due to the potential variability across periods based on timing, frequency and magnitude.
https://www.avient.com/sites/default/files/2025-03/ISO 13485 2025.pdf
Validity Avient Switzerland GmbH Hauptstrasse 30 4127 Birsfelden Switzerland Design and manufacture of colour and additive concentrates and specialty compounds for the Healthcare and Medical device market.
Ltd. 30, Hsing Pang Road 33068 Taoyuan Taiwan Design and manufacture of colour and additive concentrates and specialty compounds for the Healthcare and Medical device market.
Lewiston, ME, 04240 United States of America Design and manufacture of colour and additive concentrates and specialty compounds for the Healthcare and Medical device market.